Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genome Research Limited manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active for the company. This 1 pending office action suggests a streamlined prosecution process at this stage of the company's intellectual property development.
The portfolio's activity is limited to 1 distinct examiner and 1 distinct art unit. The busiest examiner identified is PAULUS, ERIN VIRGINIA, who is responsible for 1 pending office action. This concentration within 1 distinct art unit implies that the technical content of the pending application is specialized within the Biotechnology & Pharmaceuticals field.
Because there is only 1 distinct examiner, the applicant can focus on a singular prosecution path. Practitioners do not have to worry about divergent examiner behaviors or conflicting requirements from multiple USPTO units. The entire weight of the company's current pending matters rests with PAULUS, ERIN VIRGINIA, making this examiner's specific feedback the primary focus for the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17283939 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | GODDARD, LAURA B | 56d |
| 18012400 | CULTURE OF ORGANOIDS | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17283939 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | GODDARD, LAURA B | 56d |
| 18012400 | CULTURE OF ORGANOIDS | PAULUS, ERIN VIRGINIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012400 | CULTURE OF ORGANOIDS | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 17283939 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | GODDARD, LAURA B | 1642 | §103§112 | Non-Final OA | 56d | Pending | Apr 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial